Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 1
2020 9
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Breast cancer (BRCA) gene testing in ovarian cancer.
Chelariu-Raicu A, Coleman RL. Chelariu-Raicu A, et al. Chin Clin Oncol. 2020 Oct;9(5):63. doi: 10.21037/cco-20-4. Epub 2020 Aug 19. Chin Clin Oncol. 2020. PMID: 32819112 Free article.
Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer.
Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Kim MS, et al. Among authors: chelariu raicu a. Mol Cancer Ther. 2020 Sep 17:molcanther.0030.2020. doi: 10.1158/1535-7163.MCT-20-0030. Online ahead of print. Mol Cancer Ther. 2020. PMID: 32943548
Fertility preservation in rare ovarian tumors.
Chelariu-Raicu A, Cobb LP, Gershenson DM. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2021 Mar;31(3):432-441. doi: 10.1136/ijgc-2020-001775. Int J Gynecol Cancer. 2021. PMID: 33649010 Review.
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
Chelariu-Raicu A, Nick A, Urban R, Gordinier M, Leuschner C, Bavisotto L, Molin GZD, Whisnant JK, Coleman RL. Chelariu-Raicu A, et al. Gynecol Oncol. 2021 Feb;160(2):418-426. doi: 10.1016/j.ygyno.2020.11.013. Epub 2020 Nov 23. Gynecol Oncol. 2021. PMID: 33243443
14 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page